Syndax Pharmaceuticals (SNDX) Operating Income: 2015-2020
Historic Operating Income for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Dec 2020 value amounting to -$19.9 million.
- Syndax Pharmaceuticals' Operating Income fell 39.81% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 24.13%. This contributed to the annual value of -$339.7 million for FY2024, which is 47.71% down from last year.
- Per Syndax Pharmaceuticals' latest filing, its Operating Income stood at -$19.9 million for Q4 2020, which was down 0.04% from -$19.9 million recorded in Q3 2020.
- In the past 5 years, Syndax Pharmaceuticals' Operating Income registered a high of -$8.6 million during Q2 2016, and its lowest value of -$19.9 million during Q4 2020.
- Its 3-year average for Operating Income is -$17.1 million, with a median of -$17.2 million in 2018.
- As far as peak fluctuations go, Syndax Pharmaceuticals' Operating Income tumbled by 160.12% in 2016, and later climbed by 26.52% in 2019.
- Quarterly analysis of 5 years shows Syndax Pharmaceuticals' Operating Income stood at -$11.1 million in 2016, then crashed by 74.93% to -$19.5 million in 2017, then rose by 0.80% to -$19.3 million in 2018, then climbed by 26.52% to -$14.2 million in 2019, then slumped by 39.81% to -$19.9 million in 2020.
- Its Operating Income was -$19.9 million in Q4 2020, compared to -$19.9 million in Q3 2020 and -$16.6 million in Q2 2020.